A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Trial Profile

A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Avacincaptad pegol (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 04 May 2016 According to an OphthoTech Corporation media release, the first patient was dosed during the first quarter of 2016.
    • 29 Jan 2016 Status changed from planning to recruiting according to an Ophthotech Corporation media release.
    • 05 Nov 2015 According to an Ophthotech Corporation media release, this trial is expected to begin in the end of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top